From import dependence to global leadership, the next phase of growth must be driven not only by manufacturing scale and policy support, but also by innovation, research, and globally competitive healthcare technologies
The move marks one of the most significant coverage expansions yet in obesity care, bringing FDA-approved treatment options further into mainstream insurance plans rather than out-of-pocket reach
The company is set to unveil new clinical data across obesity, diabetes, kidney, and liver disease programs
The Establishment Inspection Report came following closure of a product- specific pre-approval inspection from March 2 to March 7, 2026
POSEIDON is among the largest global datasets to quantify this residual inflammatory burden
The decision now moves to the European Commission, with a final ruling expected by the third quarter of 2026
The trial will assess Precem-TcT, both as monotherapy and in combination with bevacizumab, in patients whose disease has progressed after or become resistant to standard treatments
Clears major obesity endpoints at 80 weeks
Q4FY26 revenue rises 13.6% to Rs. 14,560 crore; quarterly net profit jumps 26.2% to Rs. 2,714 crore driven by India business and Innovative Medicines growth
Pfizer says the broader dataset across all 25 serotypes strengthens confidence that the program can meet non-inferiority thresholds in its upcoming Phase 3 pediatric trials
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
